NCLEX Review Guide: Kawasaki Disease

Definition and Epidemiology

• Kawasaki Disease (KD) is an acute, self-limited vasculitis that primarily affects children under 5 years of age, with peak incidence between 18-24 months. It is the leading cause of acquired heart disease in children in developed countries.
• The etiology remains unknown, but it likely involves an abnormal immune response to an infectious trigger in genetically predisposed individuals. Seasonal patterns and occasional outbreaks suggest an infectious component.

Diagnostic Criteria

• Diagnosis requires fever for ≥5 days plus at least 4 of 5 principal clinical features: polymorphous rash, bilateral conjunctival injection, changes in lips and oral cavity, changes in extremities, and cervical lymphadenopathy.
• Incomplete Kawasaki Disease refers to patients with fever and fewer than 4 principal symptoms but with laboratory evidence and/or echocardiographic findings consistent with KD.

Principal Clinical Features

• Polymorphous rash: Typically appears within 5 days of fever onset. The rash is often widespread, maculopapular, and may involve the trunk, extremities, and perineal area without vesicles or crusts.
• Bilateral conjunctival injection: Non-exudative, limbic sparing (area around iris remains clear), without significant eye pain or exudate.
• Changes in lips and oral cavity: Includes erythema, dryness, fissuring and cracking of lips, strawberry tongue (prominent papillae), and diffuse erythema of oral and pharyngeal mucosa.
• Changes in extremities: Acute phase - erythema and edema of hands and feet; subacute phase (2-3 weeks after onset) - periungual desquamation beginning at fingertips.
• Cervical lymphadenopathy: At least one lymph node >1.5 cm in diameter, usually unilateral, firm, and non-fluctuant.

Associated Clinical Findings

• Cardiovascular manifestations include myocarditis, pericarditis, valvular regurgitation, and most importantly, coronary artery aneurysms, which occur in 15-25% of untreated patients.
• Non-cardiac manifestations may include arthritis/arthralgia, aseptic meningitis, pneumonitis, uveitis, gastroenteritis, urethritis, and otitis media. Irritability is a nearly universal finding and can be extreme.

Laboratory Abnormalities

• Common laboratory findings include elevated ESR and CRP, leukocytosis with neutrophilia, normocytic anemia, thrombocytosis (typically after 1 week), hypoalbuminemia, and elevated liver enzymes.
• Urinalysis may show sterile pyuria, and CSF may demonstrate aseptic meningitis with predominance of mononuclear cells.

Cardiac Evaluation

• Echocardiography is the primary imaging modality to assess for coronary artery abnormalities. Initial echocardiogram should be performed at diagnosis, with follow-up studies based on risk stratification.
• ECG findings may include prolonged PR interval, ST-T wave changes, and arrhythmias, though these are non-specific.

Acute Phase Treatment

• The standard treatment consists of high-dose intravenous immunoglobulin (IVIG) at 2 g/kg as a single infusion, along with high-dose aspirin (80-100 mg/kg/day divided into 4 doses) until the patient is afebrile for 48-72 hours.
• IVIG should be administered within the first 10 days of illness to reduce the risk of coronary artery aneurysms. Approximately 10-20% of patients may be resistant to initial IVIG therapy and require additional treatment.

Subacute and Convalescent Phase Management

• After the acute phase, aspirin is reduced to low-dose (3-5 mg/kg/day) and continued for 6-8 weeks if no coronary abnormalities are detected. For patients with coronary aneurysms, low-dose aspirin is continued indefinitely.
• Long-term management depends on the degree of coronary involvement and may include antiplatelet therapy, anticoagulation, beta-blockers, and lifestyle modifications to reduce cardiovascular risk.

Nursing Considerations

1. Administer IVIG slowly according to facility protocol, typically over 10-12 hours, and monitor vital signs frequently.
2. Provide antipyretics as ordered for fever and comfort measures for associated symptoms.
3. Monitor for signs of cardiac involvement including tachycardia, gallop rhythm, and decreased peripheral perfusion.
4. Provide education to parents regarding medication administration, follow-up appointments, and signs/symptoms requiring immediate medical attention.
5. Implement isolation precautions as appropriate until infectious causes are ruled out.

Cardiac Complications

• Coronary artery aneurysms are the most serious complication, occurring in 15-25% of untreated patients and 3-5% of appropriately treated patients. Risk factors for aneurysm development include male gender, age <1 year or >5 years, delayed diagnosis, persistent fever after IVIG, and laboratory markers of severe inflammation.
• Long-term complications may include coronary artery stenosis, thrombosis, myocardial infarction, and rarely, sudden death.

Prognosis

• With timely IVIG treatment, the prognosis for most patients is excellent. More than 90% of treated patients recover without significant cardiac sequelae.
• Patients with persistent coronary abnormalities require lifelong cardiac follow-up and may have increased risk of premature atherosclerosis and coronary events in adulthood.

Kawasaki Disease vs. Other Conditions

Incomplete vs. Complete Kawasaki Disease

• Complete Kawasaki Disease meets the classic diagnostic criteria of fever ≥5 days plus 4 of 5 principal clinical features.
• Incomplete Kawasaki Disease has prolonged fever but fewer than 4 principal features, with supporting laboratory evidence and/or echocardiographic findings.

Memory Aids

Common Pitfalls

• Not all features need to be present simultaneously. The clinical features may appear sequentially, and some may have resolved by the time others appear.
• Incomplete KD is often missed or diagnosed late. Consider KD in any child with unexplained fever for ≥5 days, especially in infants.
• Laboratory values change over time. Thrombocytosis typically occurs in the second week, so normal platelet count early in the illness does not rule out KD.

NCLEX Question Strategies

• For diagnostic questions, focus on the combination of fever duration and principal features. Remember that fever for ≥5 days is mandatory.
• For treatment questions, know the standard therapy (IVIG + aspirin) and the transition from high-dose to low-dose aspirin.
• For nursing care questions, prioritize cardiac monitoring, IVIG administration safety, and parent education.

Quick Check

Knowledge Checklist

• I can describe the diagnostic criteria for Kawasaki Disease
• I understand the difference between complete and incomplete Kawasaki Disease
• I know the standard treatment protocol including IVIG and aspirin therapy
• I can identify the major cardiac complications
• I understand the nursing considerations for patients with Kawasaki Disease
• I can differentiate Kawasaki Disease from other similar conditions
• I know the risk factors for developing coronary artery aneurysms
• I understand the long-term follow-up recommendations

• Kawasaki Disease is an acute, self-limited vasculitis primarily affecting children under 5 years of age.
• Diagnosis requires fever ≥5 days plus at least 4 of 5 principal clinical features: polymorphous rash, bilateral conjunctival injection, changes in lips and oral cavity, changes in extremities, and cervical lymphadenopathy.
• Coronary artery aneurysms are the most serious complication, occurring in 15-25% of untreated patients and 3-5% of appropriately treated patients.
• Standard treatment includes IVIG (2 g/kg) as a single infusion and high-dose aspirin (80-100 mg/kg/day) until the patient is afebrile, followed by low-dose aspirin (3-5 mg/kg/day).
• Treatment within the first 10 days of illness significantly reduces the risk of coronary artery abnormalities.
• Incomplete Kawasaki Disease presents with fever but fewer than 4 principal features and requires a high index of suspicion.
• Long-term management and follow-up depend on the degree of coronary involvement.